Two immune drugs, with or without targeted brain radiation, for melanoma that spread to the brain
Official title: Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial asks if adding targeted brain radiation to two immune drugs works better than the drugs alone.
Read our full plain-language summary
What the trial team says
This is a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain metastases.
Key facts
- Registry number
- NCT03340129
- Stage of testing
- Phase 2
- Conditions studied
- Melanoma Stage Iv
Where it is running
This trial lists 9 sites.
-
New South Wales
- Westmead Hospital (Sydney)
- Calvary Mater NewcastleHospital (Waratah)
- Melanoma Institute Australia (Wollstonecraft)
-
Oslo
- Oslo Univesity Hospital Radiumhospitalet (Oslo)
-
Queensland
- Princess Alexandra Hospital (Woolloongabba)
-
South Australia
- Royal Adelaide Hospital (Adelaide)
-
Victoria
- Peter MacCallum Cancer Centre (East Melbourne)
- Alfred Hospital (Melbourne)
-
Western Australia
- Sir Charles Gairdner Hosptial (Perth)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.